S. aureus CRISPR/Cas9 Antibody
Monoclonal antibody raised in mouse against the N-terminus of the S. aureus Cas9 nuclease (CRISPR-associated protein 9) using a recombinant protein.
| Lot | 10µg/50µg: 001 // 100µg: 002 |
|---|---|
| Concentration | 2 μg/μl |
| Species reactivity | Mouse |
| Type | Monoclonal |
| Purity | Protein G purified |
| Host | Mouse |
| Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
| Applications | Suggested dilution | References |
|---|---|---|
| Western Blotting | 1:4,000 | Fig 1 |
| Immunoprecipitation | 5 μg/IP | Fig 2 |
| Immunofluorescence | 1:400 | Fig 3 |
-
C15310260-100S. aureus CRISPR/Cas9 Antibody (N-terminal)
-
C15310259-100
S. aureus CRISPR/Cas9 Antibody (C-terminal)
Validation data
Figure 1. Western blot analysis using the Diagenode monoclonal antibody directed against S. aureus CRISPR/ Cas9
Western blot was performed on protein extracts from HEK293 cells (lane 1), HEK293 cells transfected with S. aureus CRISPR/Cas9 (lane 2) and HeLa cells transfected with S. pyogenes Cas9 (lane 3) using the Diagenode antibody against CRISPR/Cas9 (Cat. No. C15200230), diluited 1:4,000 in PBS-T containing 3% NFDM. The marker is shown on the left, position of the Cas9 protein is indicated on the right.
Figure 2. IP using the Diagenode monoclonal antibody directed against S. aureus CRISPR/Cas9
IP was performed on whole cell extracts (200 μg) from HEK293 cells transfected with a Cas9 expression vector (lane 1, 3 and 5), or untransfected cells (lane 2, 4 and 6) using 5 μg of the Diagenode antibody against CRISPR/Cas9 (Cat. No. C15200230). The immunoprecipitated proteins were subsequently analysed by Western blot. The results obtained with the Cas9 antibody are shown in lane 3 and 4. The negative control (IP with beads only) is shown in lane 5 and 6, the input (10 μg) is shown in lane 1 and 2.
Figure 3. Immunofluorescence using the Diagenode monoclonal antibody directed against S. aureus CRISPR/Cas9
Transiently transfected U2OS cells expressing SaCas9-T2A-GFP were fixed with 3.7% formaldehyde, permeabilized in 0.5% Triton-X-100 and blocked in PBS containing 2% BSA for 2 hours at RT. The cells were stained with the S. aureus CRISPR/Cas9 antibody (cat. No. C15200230) diluted 1:400 in blocking solution at 4°C o/n, followed by incubation with an anti-mouse secondary antibody coupled to DyLight594 for 1 h at RT (left figure). Nuclei were counter-stained with Hoechst 33342 (right). The middle figure shows IF with an anti-GFP antibody.
Target Description
CRISPR systems are adaptable immune mechanisms which are present in many bacteria to protect themselves from foreign nucleic acids, such as viruses, transposable elements or plasmids. The CRISPR/Cas9 (CRISPR-associated protein 9 nuclease) system from S. pyogenes was the first to be adapted for inducing sequence-specific double stranded breaks and targeted genome editing. This system is unique and flexible due to its dependence on RNA as the moiety that targets the nuclease to a desired DNA sequence and can be used to induce indel mutations, specific sequence replacements or insertions and large deletions or genomic rearrangements at any desired location in the genome. In addition, Cas9 can also be used to mediate upregulation of specific endogenous genes or to alter histone modifications or DNA methylation, Recently, the CRISPR/Cas9 from S. aureus (UniProtKB/Swiss-Prot entry J7RUA5) was also shown to be suitable for humane genome editing. The S. aureus CRISPR/Cas9 has the advantage that it’s smaller and therefore easier to transfect cells with, whereas the efficiency and specificity are similar.
Applications
| WB Western blot : The quality of antibodies used in this technique is crucial for correct and specific protein identification. Diagenode offers huge selection of highly sensitive and specific western blot-validated antibodies. Learn more about: Load... Read more |
| IF Immunofluorescence: Diagenode offers huge selection of highly sensitive antibodies validated in IF. Immunofluorescence using the Diagenode monoclonal antibody directed against CRISPR/Cas9 HeLa cells transfected with a Cas9 expression vector (... Read more |
| IP Immunoprecipitation Read more |
Documents
| Antibodies you can trust POSTER Epigenetic research tools have evolved over time from endpoint PCR to qPCR to the analyses of lar... | Download |
| Epigenetic Antibodies Brochure BROCHURE More than in any other immuoprecipitation assays, quality antibodies are critical tools in many e... | Download |
| Accurate QC to optimize CRISPR/Cas9 genome editing specificity POSTER The CRISPR/Cas9 technology is delivering superior genetic models for fundamental disease res... | Download |
| S. aureus CRISPR/Cas9 monoclonal antibody tds DATASHEET Datasheet of the S. aureus CRISPR/Cas9 monoclonal antibody | Download |
Safety sheets
| S.aureus CRISPR/Cas9 antibody SDS US en | Download |
| S.aureus CRISPR/Cas9 antibody SDS GB en | Download |
| S.aureus CRISPR/Cas9 antibody SDS BE fr | Download |
| S.aureus CRISPR/Cas9 antibody SDS ES es | Download |
| S.aureus CRISPR/Cas9 antibody SDS JP ja | Download |
| S.aureus CRISPR/Cas9 antibody SDS DE de | Download |
| S.aureus CRISPR/Cas9 antibody SDS BE nl | Download |
| S.aureus CRISPR/Cas9 antibody SDS FR fr | Download |
Publications
How to properly cite our product/service in your workWe strongly recommend using this: S. aureus CRISPR/Cas9 Antibody (Hologic Diagenode Cat# C15200230-100 Lot# 10µg/50µg: 001 // 100µg: 002). Click here to copy to clipboard. Using our products or services in your publication? Let us know! |
Life-Long AAV-Mediated CRISPR Genome Editing in Dystrophic Heart Improves Cardiomyopathy without Causing Serious Lesions in mdx Mice. |
Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy. |
CRISPR-mediated activation of a promoter or enhancer rescues obesity caused by haploinsufficiency. |